Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …

Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing lung disorder of
unknown aetiology whose diagnosis involves the careful exclusion of secondary causes for …

This is a time of substantial progress in the evaluation and care of patients with idiopathic
pulmonary fibrosis (IPF). In addition to the approval and widespread availability of the first …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disorder
showcasing an interaction between genetic predisposition and environmental risks. This …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease
associated with dyspnoea, cough and impaired quality of life. Currently, the aims of patient …

Idiopathic pulmonary fibrosis (IPF), the most lethal form of interstitial pneumonia of unknown
cause, is associated with a specific radiological and histopathological pattern (the so-called …

Background Pirfenidone is currently approved in the EU for the treatment of mild to moderate
idiopathic pulmonary fibrosis (IPF) and offers a beneficial risk-benefit profile. However, there …

The currently accepted approach to treatment of idiopathic pulmonary fibrosis (IPF) is based
on the assumption that it is a chronic inflammatory disease, and most available …